9 January 2018 - Ozempic demonstrated clinically meaningful improvements in blood sugar and body weight vs comparators.

Novo Nordisk announced today that Health Canada has approved Ozempic (semaglutide injection) as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, when metformin is not tolerated or contraindicated.1 Ozempic, a once-weekly glucagon-like peptide 1 (GLP-1) receptor agonist, can also be used together with other anti-diabetic drugs, when diet and exercise do not achieve adequate glycemic control.

Ozempic was extensively studied in the SUSTAIN clinical trial program, which involved more than 8,000 adults with type 2 diabetes. In the SUSTAIN program, Ozempic was studied in combination with oral anti-diabetic agents and basal insulin.

Read Novo Nordisk press release